Business Context and Reporting Period
Company: ACME UNITED CORP
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2000
Business Overview: The Company manufactures and distributes office products. Sales are seasonal, typically stronger in the second and third quarters due to the back-to-school season. The Company sold its medical division in March 1999, which is reported as discontinued operations.
Key Financial Metrics
All amounts in thousands, except per share data.
| Metric | Three Months Ended Sep 30, 2000 | Nine Months Ended Sep 30, 2000 |
|---|---|---|
| Net Sales | $8,760 | $27,003 |
| Gross Profit | $3,148 | $9,384 |
| Gross Margin | 35.9% | 34.7% |
| Net Income (Continuing Ops) | $302 | $923 |
| Diluted EPS (Continuing Ops) | $0.08 | $0.25 |
| Cash and Equivalents | $47 | $47 (Ending Balance) |
| Working Capital | $8,164 | $8,164 (Ending Balance) |
| Total Debt | $7,918 | $7,918 (Ending Balance) |
| Current Ratio | 1.80 | 1.80 (Ending Balance) |
Material Changes vs. Prior Period
- Revenue: Net sales for the nine months ended September 30, 2000, decreased 3% to $27.0 million compared to $27.9 million in 1999. Domestic sales declined 6% for the nine-month period, while international sales increased 3%.
- Profitability: Net income from continuing operations for the nine months ended September 30, 2000, was $923,000, a significant improvement from a net loss of $281,000 in the same period of 1999. The 1999 prior period included a $2.1 million gain from the sale of the medical division (discontinued operations).
- Margins: Gross margin improved significantly to 34.7% for the nine months of 2000 versus 26.4% in 1999. This was driven by resourcing scissor products to Asia, aggressive purchasing, and improved manufacturing efficiencies.
- Expenses: SG&A expenses as a percentage of net sales increased to 28.2% for the nine months of 2000 from 26.1% in 1999. This increase is partially due to a reclassification of outgoing freight expense from net sales to selling expenses starting in Q1 2000.
- Cash Flow: Net cash used by operating activities was $771,000 for the nine months of 2000, compared to $2.7 million used in 1999. The 1999 figure was heavily impacted by the sale of the medical division and changes in working capital.
Guidance, Outlook, and Risks
- Liquidity: The Company maintains a $11.5 million revolving credit facility (maturity Jan 2003) with $1.6 million in excess availability as of September 30, 2000. Management expects cash from operations and available credit to be sufficient for the next year.
- Debt Structure: The Company entered into an interest rate swap in August 2000 to fix the rate at 10.18% on $3.5 million of debt. A separate mortgage refinance of $700,000 was also completed.
- Covenants: The Company is in compliance with all financial covenants, including tangible net worth and debt service coverage ratios.
- Risks:
- Legal: The Company is a defendant in five remaining lawsuits regarding latex products (distributed, not manufactured). Management believes there will be no material adverse impact.
- Environmental: The Company is involved in certain environmental matters but does not anticipate a material impact.
- Forward-Looking: Results are subject to risks regarding growth management, inventory levels, and general economic conditions.
Investor Verification Checklist
- Reclassification Impact: Verify the impact of reclassifying outgoing freight expenses from net sales to SG&A on year-over-year margin comparisons.
- Discontinued Operations: Confirm that the 1999 net income comparison excludes the $2.1 million gain from the sale of the medical division to accurately assess ongoing operational performance.
- Debt Covenants: Monitor compliance with the tangible net worth and debt service coverage ratios required by the $11.5 million credit facility.
- Legal Contingencies: Track the status of the five remaining latex product lawsuits to ensure no material liability emerges.
- Inventory Levels: Review the increase in inventory ($10.1 million vs $8.3 million prior year) to ensure it aligns with sales demand and does not indicate obsolescence risks.